Overview
Rhodiola extract, primarily derived from Rhodiola rosea or Rhodiola crenulata, is an adaptogenic herb traditionally used to enhance physical and mental resilience under stress. It contains bioactive compounds such as salidroside and rosavins, which are believed to modulate the hypothalamic-pituitary-adrenal (HPA) axis, reduce oxidative stress, and exert anti-inflammatory effects [7][5]. Some clinical evidence suggests potential benefits in fatigue reduction and exercise tolerance, although study quality has been variable, with several trials showing methodological limitations [3]. Preliminary research indicates possible supportive roles in metabolic health, ischemic heart disease, and chronic inflammatory conditions like COPD, but findings remain inconclusive due to small sample sizes and inconsistent methodologies [1][4][8]. Overall, Rhodiola is well tolerated in studied doses, but more rigorous trials are needed to confirm its therapeutic efficacy.
Dosage Guide
Therapeutic Doses
For treatment of specific conditions
Special Forms
Alternative forms for specific needs
Most studied form for adaptogenic and anti-fatigue effects
Used in research for metabolic and neuroprotective effects
Clinical Notes
- Generally well tolerated; mild side effects may include dizziness, dry mouth, or gastrointestinal discomfort.
- Potential stimulant effect—may cause insomnia if taken late in the day.
- Theoretical interaction with antidepressants and antipsychotics due to monoamine oxidase inhibition; use with caution in psychiatric conditions.
- Limited safety data in pregnancy and lactation—avoid due to insufficient evidence.
Research
In a 12-week RCT, 250 mg of Rhodiola crenulata twice daily was well tolerated in patients with COPD, but no significant differences were observed in lung function, exercise capacity, or quality of life compared to placebo.
Rhodiola (roseroot) was evaluated for phytochemical content using sequential extraction methods, highlighting its potential as a source of bioactive plant compounds, though no clinical outcomes were assessed.
A critical review of human studies on Rhodiola rosea found significant methodological flaws in most trials claiming benefits, with inadequate statistical analysis and selective reporting; several high-quality studies showed no significant effect.
A systematic review suggested potential benefits of Rhodiola formulations in ischemic heart disease when combined with conventional therapy, but trial quality was low and results should be interpreted cautiously.
Rhodiola and its active compound salidroside show promise in preclinical models for metabolic disorders by supporting energy homeostasis and reducing oxidative stress.
Identified new glycosides (creosides I–V) and known compounds in Rhodiola crenulata, contributing to its phytochemical profile.
Rhodiola exhibits strong antioxidant activity due to phenolic compounds like salidroside, which scavenge reactive oxygen species and may protect against oxidative stress-related diseases.
Protocol for a systematic review and meta-analysis to evaluate Rhodiola's efficacy and safety in ischemic heart disease, indicating ongoing interest but lack of conclusive evidence.
